N	Concordance
1	y and consolidation with cytarabine and mitoxantrone in patients with poor prog
2	d at  escalating doses of etoposide and mitoxantrone until the maximum tolerated
3	rpose of this study was to characterize mitoxantrone-induced cytotoxicity in KG1
4	eosomal DNA fragmentation. In contrast, mitoxantrone induced a G2-M block in res
5	ificant efficacy of the FMP fludarabine-mitoxantrone combination regimen in obta
6	ednimustine on days 1-5 and intravenous mitoxantrone on day 1 every 3 weeks.  Pa
7	greater than that induced by 0.25 mg/kg mitoxantrone (to which it is therapeutic
8	han those resulting from either dose of mitoxantrone. Apoptosis of cardiac myocy
9	myelosuppression. In clinical practice, mitoxantrone has not replaced the anthra
10	o. It is marginally less cytotoxic than mitoxantrone but much more growth-inhibi
11	owth-factor sensitivity and response to mitoxantrone treatment including the dev
12	hormone-resistant patients treated with mitoxantrone plus prednisone compared w